Woolfrey JR - Search Results

1

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS. Trowe T, et al. Among authors: woolfrey jr. Clin Cancer Res. 2008 Apr 15;14(8):2465-75. doi: 10.1158/1078-0432.CCR-07-4367. Clin Cancer Res. 2008. PMID: 18413839

2

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

Forsyth T, Kearney PC, Kim BG, Johnson HW, Aay N, Arcalas A, Brown DS, Chan V, Chen J, Du H, Epshteyn S, Galan AA, Huynh TP, Ibrahim MA, Kane B, Koltun ES, Mann G, Meyr LE, Lee MS, Lewis GL, Noguchi RT, Pack M, Ridgway BH, Shi X, Takeuchi CS, Zu P, Leahy JW, Nuss JM, Aoyama R, Engst S, Gendreau SB, Kassees R, Li J, Lin SH, Martini JF, Stout T, Tong P, Woolfrey J, Zhang W, Yu P. Forsyth T, et al. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7653-8. doi: 10.1016/j.bmcl.2012.10.007. Epub 2012 Oct 16. Bioorg Med Chem Lett. 2012. PMID: 23127890

3

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

Takeuchi CS, Kim BG, Blazey CM, Ma S, Johnson HW, Anand NK, Arcalas A, Baik TG, Buhr CA, Cannoy J, Epshteyn S, Joshi A, Lara K, Lee MS, Wang L, Leahy JW, Nuss JM, Aay N, Aoyama R, Foster P, Lee J, Lehoux I, Munagala N, Plonowski A, Rajan S, Woolfrey J, Yamaguchi K, Lamb P, Miller N. Takeuchi CS, et al. J Med Chem. 2013 Mar 28;56(6):2218-34. doi: 10.1021/jm3007933. Epub 2013 Mar 7. J Med Chem. 2013. PMID: 23394126

4

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.

Ibrahim MA, Johnson HW, Jeong JW, Lewis GL, Shi X, Noguchi RT, Williams M, Leahy JW, Nuss JM, Woolfrey J, Banica M, Bentzien F, Chou YC, Gibson A, Heald N, Lamb P, Mattheakis L, Matthews D, Shipway A, Wu X, Zhang W, Zhou S, Shankar G. Ibrahim MA, et al. J Med Chem. 2012 Feb 9;55(3):1368-81. doi: 10.1021/jm201533b. Epub 2012 Jan 24. J Med Chem. 2012. PMID: 22214363

5

The use of computational methods in the discovery and design of kinase inhibitors.

Woolfrey JR, Weston GS. Woolfrey JR, et al. Curr Pharm Des. 2002;8(17):1527-45. doi: 10.2174/1381612023394304. Curr Pharm Des. 2002. PMID: 12052199 Review.

6

Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.

Bauer SM, Goldman EA, Huang W, Su T, Wang L, Woolfrey J, Wu Y, Zuckett JF, Arfsten A, Huang B, Kothule J, Lin J, May B, Sinha U, Wong PW, Hutchaleelaha A, Scarborough RM, Zhu BY. Bauer SM, et al. Bioorg Med Chem Lett. 2004 Aug 2;14(15):4045-50. doi: 10.1016/j.bmcl.2004.05.033. Bioorg Med Chem Lett. 2004. PMID: 15225723

7

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

Zhang P, Huang W, Wang L, Bao L, Jia ZJ, Bauer SM, Goldman EA, Probst GD, Song Y, Su T, Fan J, Wu Y, Li W, Woolfrey J, Sinha U, Wong PW, Edwards ST, Arfsten AE, Clizbe LA, Kanter J, Pandey A, Park G, Hutchaleelaha A, Lambing JL, Hollenbach SJ, Scarborough RM, Zhu BY. Zhang P, et al. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2179-85. doi: 10.1016/j.bmcl.2009.02.111. Epub 2009 Mar 3. Bioorg Med Chem Lett. 2009. PMID: 19297154

8

Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors.

Su T, Yang H, Volkots D, Woolfrey J, Dam S, Wong P, Sinha U, Scarborough RM, Zhu BY. Su T, et al. Bioorg Med Chem Lett. 2003 Feb 24;13(4):729-32. doi: 10.1016/s0960-894x(02)01038-7. Bioorg Med Chem Lett. 2003. PMID: 12639568

9

Design, synthesis, and SAR of amino acid derivatives as factor Xa inhibitors.

Su T, Wu Y, Doughan B, Jia ZJ, Woolfrey J, Huang B, Wong P, Park G, Sinha U, Scarborough RM, Zhu BY. Su T, et al. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2947-50. doi: 10.1016/s0960-894x(01)00585-6. Bioorg Med Chem Lett. 2001. PMID: 11677132

10

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.

Jia ZJ, Wu Y, Huang W, Zhang P, Song Y, Woolfrey J, Sinha U, Arfsten AE, Edwards ST, Hutchaleelaha A, Hollennbach SJ, Lambing JL, Scarborough RM, Zhu BY. Jia ZJ, et al. Bioorg Med Chem Lett. 2004 Mar 8;14(5):1229-34. doi: 10.1016/j.bmcl.2003.12.054. Bioorg Med Chem Lett. 2004. PMID: 14980671

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page